FDA approves J&J diabetes combo; Sanofi launches Eloxatin generic;

@FiercePharma: Tops on FP Monday: Former top Sanofi exec Whitaker nabbed by Synta to shuttle cancer drug to market. Article | Follow @FiercePharma

@EricPFierce: RT @FiercePharma: Boehringer Ingelheim cutting jobs in Germany in 15% cost reduction move. Story | Follow @EricPFierce

@CarlyHFierce: Generic Viagra Delivers Hidden Billionaire Duo in Brazil. Bloomberg story | Follow @CarlyHFierce

> The FDA has approved Johnson & Johnson's ($JNJ) diabetes combo of Invokana and metformin. Story

> Sanofi ($SNY) has launched an authorized generic of colorectal cancer drug Eloxatin. Release

> Merck ($MRK) CEO Kenneth Frazier unloaded 10,058 shares of the company's stock in a transaction dated Monday, Aug. 11. Report

> Switzerland's Galenica will split into two separate companies, with Shire ($SHPG) vet Soeren Tulstrup heading up the Vifor pharma unit. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Imaging pen may detect skin cancer faster. Article | Follow @FierceMedDev

@StacyALawrence: Med tech M&A gets much, much bigger during the first half. Special report | Follow @StacyALawrence

@VarunSaxena2: ICYMI last week: UPDATED with information from interview of CEO: NeuroPace RNS Stimulator secures add-on payments from CMS. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists created a 3-D, doughnut-shaped model of the human brain that can imitate neurological function. More from the NYT | Follow @EmilyWFierce

> Lenox MacLaren's grinding court battle with Medtronic will continue. Report

> UCLA researchers develop wearable biosensor for detecting GI disorder postsurgery. More

> Smaller med techs suffer under excise tax burden. Story

> Danish devicemaker homes in on next-generation hearing aid to jump-start sales. Article

Biotech News

@FierceBiotech: ICYMI yesterday: J&J's diabetes combo wins FDA nod in a fast-crowding space. Article | Follow @FierceBiotech

@DamianFierce: Digging into the FDA's priority review voucher. Who's willing to pay big for one? Report | Follow @DamianFierce

@EmilyMFierce: Gene editing method kills cervical cancer cells. More from FierceBiotech Research | Follow @EmilyMFierce

> Tokai pitches a $75M IPO to fund its three-in-one cancer drug. News

> Intercept leaps again as deeper NASH data quiet some fears. Story

> UniQure bets on a gene therapy for heart failure. Article

Biotech Research News

> 3-D bioengineered brain tissue grown in lab. Report

> Small molecule inhibitor reverses cognitive deficits of Alzheimer's in mice. More

> Glaxo: Ebola vaccine could be ready by 2015. Item

> Malaria vaccine alternative shows high protection in mice. Article

> Gene editing method kills cervical cancer cells. Story

Pharma Manufacturing News

> Baxter to add recombinant protein processing suite at Singapore plant. More

> Recalls overseen by FDA soar in 2013, 2014. Item

> Report: Immigrants make up 26% of U.S. drug production and distribution workforce. Story

> Pakistan indicts 76 customs officers in fake drug probe. News

> U.S. health emergency facilities ready to produce Ebola drugs. Article

And Finally... Cancer Research UK is calling upon the medical community to become more involved with Wikipedia to ensure better accuracy of information. More

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.